DSM : 2Q21 EBITDA 5% beat; expect 2021 consensus +1%
>2Q21 adjusted EBITDA 5% ahead of consensus - DSM reported better than expected 2Q21 results. Sales of € 2,294m were up 14% yoy and 3% ahead of consensus (Vara). Volumes were up 14%, while price/mix was down 2%. Adjusted EBITDA of € 484m was up 30% yoy and 5% ahead of consensus. Nutrition revenues were up 5% yoy at € 1,726m, 1% ahead of consensus. Adjusted EBITDA of € 378m was up 8% yoy and 1% ahead of consensus, as the EBITDA margin was 10bps above consensus at 21.9%...Royal DSM is engaged in the creation of products and services in Life Sciences and Materials Sciences. Co.'s products and services are used globally in range of markets and applications in healthcare, pharmaceutical automotive and chemicals sectors. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. The activities of Co. are grouped into four clusters: Nutrition, Pharma, Performance Materials and Polymer Intermediates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.